Previous 10 | Next 10 |
PTC Therapeutics has been cooperating with Roche since 2011. Evrysdi's sales were CHF 206 million in the fourth quarter of 2021, up 338% from the fourth quarter of 2020. PTC Therapeutics management expects the company's revenue of $700-750 million in 2022, which is 34.6% more than...
PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire SOUTH PLAINFIELD, N.J. , April 8, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 8, 2022 , the company approved ...
PTC Therapeutics Announces Initiation of PIVOT-HD Phase 2 Clinical Trial to Evaluate PTC518 in Patients with Huntington's Disease PR Newswire SOUTH PLAINFIELD, N.J. , March 30, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the...
New York, New York--(Newsfile Corp. - March 22, 2022) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of PTC Therapeutics, Inc. (NASDAQ: PTCT) breached their fiduciary duties to shareholders. The investigation concerns ...
PTC Therapeutics to Present New Data at the 2022 Muscular Dystrophy Association Clinical & Scientific Conference PTC Therapeutics to Present New Data at the 2022 Muscular Dystrophy Association Clinical & Scientific Conference PR Newswire SOUTH PLAINFIELD, N...
PTC Therapeutics, Inc. (PTCT) Q4 2021 Earnings Conference Call February 22, 2022, 16:30 ET Company Participants Kylie O'Keefe - VP, Head of Global Strategic Marketing & Business Intelligence Stuart Peltz - Co-Founder & CEO Matthew Klein - COO Eric Pauwels - Chief Business Officer Emil...
PTC Therapeutics press release (NASDAQ:PTCT): Q4 GAAP EPS of -$2.03 misses by $0.34. Revenue of $165.2M (+39.0% Y/Y) beats by $4.12M. For further details see: PTC Therapeutics GAAP EPS of -$2.03 misses by $0.34, revenue of $165.2M beats by $4.12M
PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results - $539 million 2021 total revenue representing impressive 41% year-over-year growth - - Continued pipeline progress with five registration-directed clinical trials on...
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2021 Financial Results PR Newswire SOUTH PLAINFIELD, N.J. , Feb. 8, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcas...
FDA Grants Evrysdi® Priority Review Based on Results From Treating Pre-Symptomatic Infants with Spinal Muscular Atrophy - RAINBOWFISH study interim results showed that after treatment with Evrysdi pre-symptomatic infants with spinal muscular atrophy achieved same motor mile...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....